Distinguished in Scleroderma

Torsten H. Witte

Medizinische Hochschule Hannover Carl Neuberg Str. 1, 
Hannover, NI, DE 
Distinguished in Scleroderma
Medizinische Hochschule Hannover Carl Neuberg Str. 1, 
Hannover, NI, DE 
OverviewLocationsClinical Research

Overview

Torsten Witte practices in Hannover, Germany. Witte is rated as a Distinguished expert by MediFind in the treatment of Scleroderma. Their top areas of expertise are Sjogren Syndrome, Dry Mouth, Dry Eye Syndrome, and Common Variable Immune Deficiency.

Their clinical research consists of co-authoring 322 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 28 articles in the study of Scleroderma.

Locations

Medizinische Hochschule Hannover Carl Neuberg Str. 1, Hannover, NI 30625, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 104-Week Study to Evaluate the Efficacy and Safety of Belimumab Administered in Combination With Rituximab to Adult Subjects With Systemic Lupus Erythematosus (SLE)
A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 104-Week Study to Evaluate the Efficacy and Safety of Belimumab Administered in Combination With Rituximab to Adult Subjects With Systemic Lupus Erythematosus (SLE)
Enrollment Status: Completed
Publish Date: February 18, 2025
Intervention Type: Drug
Study Drugs: Rituximab, Standard therapy (Including Immunosuppressants), Standard therapy (Excluding Immunosuppressants), Steroid Taper
Study Phase: Phase 3
Study Protocol for a Multi-Centre, Placebo-Controlled Phase II Study of Canakinumab for the Treatment of Adult-onset Still's Disease (AOSD) Including an Open-label Long Term Extension
Study Protocol for a Multi-Centre, Placebo-Controlled Phase II Study of Canakinumab for the Treatment of Adult-onset Still's Disease (AOSD) Including an Open-label Long Term Extension
Enrollment Status: Terminated
Publish Date: August 07, 2020
Intervention Type: Drug
Study Phase: Phase 2
View 1 Less Clinical Trial

321 Total Publications

Effects of LP.8.1-adapted mRNA vaccination on SARS-CoV-2 variant neutralisation.
Effects of LP.8.1-adapted mRNA vaccination on SARS-CoV-2 variant neutralisation.
Journal: The Lancet. Infectious diseases
Published: October 13, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Witte's expertise for a condition
ConditionClose
View All 8 Distinguished Conditions
View All 13 Advanced Conditions
View All 54 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile